Proceeds from financing completed simultaneously with reverse merger to be used to fund pipeline which includes programs licensed from Ligand
Ligand Pharmaceuticals Incorporated partner Seelos Therapeutics, Inc. announced that it has closed a reverse merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc., is publicly traded on the Nasdaq Capital Market under the trading symbol “SEEL,” and will focus on the development and commercialization of central nervous system therapeutics with known mechanisms of action in areas with high unmet medical need. Seelos is led by Chairman and Chief Executive Officer Raj Mehra, Ph.D. In conjunction with the reverse merger transaction, Seelos issued common stock and warrants for an aggregate purchase price of $18 million.
In September 2016, Ligand licensed rights to four programs to Seelos, which include:
- SLS-006 (formerly known as aplindore): first-in-class, small molecule, partial dopamine agonist for Parkinson’s disease. SLS-006 has successfully completed Phase 2 studies. Seelos intends to meet with the U.S. Food and Drug Administration and the European Medicines Authority to discuss plans for pivotal registration studies to commence in 2019. SLS-006 has shown efficacy in early-stage Parkinson’s disease patients as a monotherapy and as a potential adjunctive therapy in late-stage Parkinson’s disease patients upon co-administration with a low dosage of L-Dopa.
- SLS-008: once-daily, oral CRTh2 (Chemo-attractant Receptor-homologous molecule expressed on Th2 cells) that focuses on an undisclosed pediatric orphan indication. Seelos intends to file an Investigational New Drug application with the FDA for this pediatric orphan indication.
- SLS-010: oral histamine 3 receptor inverse agonist that has shown activity in narcolepsy and related disorders.
- SLS-012: Captisol-enabled injectable acetaminophen therapy for post-operative pain management.
Date: January 28, 2019
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Ligand